Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Concurrent eating disorders represent one of the most challenging issues in the management of type 1 diabetes mellitus: a vicious loop of disturbed eating behaviors, reduced metabolic control, and psychological distress is associated with poor clinical outcome. The risk factors and available treatment options for concurrent eating disorders are discussed in this Viewpoint.
Hypopituitary adults with untreated growth hormone deficiency (GHD) have reduced life expectancy from cardiovascular disease. The positive effects of GH on cardiac structure and function have, therefore, been advocated in favor of GH replacement therapy for such patients. The relevance of these effects to GHD management is discussed in this Viewpoint.
A range of analogs are being tested for their ability to reproduce or enhance the beneficial effects of thyroid hormone while minimizing its less-desirable actions in particular situations. This review describes the best-studied of these agonists and receptor-antagonists, detailing their effects on cardiac function, lipid metabolism and weight loss.
Recombinant human TSH (rhTSH) is now available for use in patients with thyroid cancer. As discussed in this article, it is used as preparation before radioiodine-mediated thyroid-remnant ablation and to stimulate serum thyroglobulin levels. Using rhTSH avoids many of the unwanted effects caused by withdrawal of levothyroxine therapy.
The success of anti-HIV therapy using antiretroviral drug combinations has been tempered by metabolic effects—especially body-fat distribution, insulin tolerance, dyslipidemia, and bone demineralization. This article details the clinical, biological and therapeutic consequences of altered metabolism resulting from interactions of anti-HIV drugs with HIV and with non-HIV-related parameters.
